Background: Serum pancreastatin has greater sensitivity and specificity in diagnosing neuroendocrine tumors (NETs) than serum chromogranin A (1). Additionally, elevated pancreastatin levels are associated with worse progression free survival and overall survival in small bowel and pancreatic NETs (2). In this study, we investigated the clinical significance of elevated serum pancreastatin in identifying metastatic disease to the liver.
PST = pancreastatin, CGA = chromogranin A, PPV = positive predictive value, NPV = negative predictive value. * Sites include: pancreas (n = 10), lungs (n = 10), and unknown (n = 10), stomach (n = 1), large bowel (n = 1), and rectum (n = 1).
